Population Pharmacokinetics Analysis of Pemigatinib in Patients With Advanced Malignancies
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1038
Abstract: Pemigatinib is a fibroblast growth factor receptor 1–3 inhibitor used to treat cholangiocarcinoma. A compartmental population pharmacokinetics model was developed using data from 318 patients with cancer enrolled in a phase 1 dose‐escalation/dose‐expansion study, a… read more here.
Keywords: pharmacokinetics analysis; typical pemigatinib; population pharmacokinetics; model ... See more keywords
FGFR blockade by pemigatinib treats naïve and castration resistant prostate cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer letters"
DOI: 10.1016/j.canlet.2021.11.030
Abstract: Prostate cancer (PCa) is a leading cause of cancer mortality in the male population commonly treated with androgen deprivation therapy (ADT) and relapsing as aggressive and androgen-independent castration-resistant prostate cancer (CRPC). In PCa the FGF/FGFR… read more here.
Keywords: cancer; castration resistant; pemigatinib; pca ... See more keywords
Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.1c00713
Abstract: Aberrant activation of FGFR has been linked to the pathogenesis of many tumor types. Selective inhibition of FGFR has emerged as a promising approach for cancer treatment. Herein, we describe the discovery of compound 38… read more here.
Keywords: potent selective; inhibitor; pemigatinib; fgfr ... See more keywords
Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2022.2150168
Abstract: ABSTRACT Introduction Cholangiocarcinoma (CCA) accounts for approximately 3% of gastrointestinal malignancies and is associated with a high mortality rate. Recent progress in the understanding of cholangiocarcinoma tumorigenesis and molecular markers has led to the development… read more here.
Keywords: fgfr; fusion; cca; cholangiocarcinoma ... See more keywords
Pemigatinib for the treatment of myeloid/lymphoid neoplasms with FGFR1 rearrangement
Sign Up to like & getrecommendations! Published in 2023 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2023.2192930
Abstract: ABSTRACT Introduction Myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangements (MLNFGFR1) are rare entities with aggressive features and poor prognosis. Presentation is heterogeneous, ranging from myeloproliferative neoplasms (with or without eosinophilia) to T-cell lymphoma… read more here.
Keywords: lymphoid neoplasms; fgfr1; pemigatinib; treatment ... See more keywords
Basal cell carcinoma of the prostate: a case report responding to the FGFR inhibitor pemigatinib and literature review
Sign Up to like & getrecommendations! Published in 2022 at "Current Opinion in Urology"
DOI: 10.1097/mou.0000000000001007
Abstract: Purpose of review Due to the limited number of cases, there are no guidelines for basal cell carcinoma (BCC) of the prostate. This review combines an unpublished case report of a 55-year-old patient with BCC… read more here.
Keywords: bcc; review; prostate; basal cell ... See more keywords
Pemigatinib in the Real-World Management of Cholangiocarcinoma Through a Canadian Patient Support Program
Sign Up to like & getrecommendations! Published in 2025 at "Current Oncology"
DOI: 10.3390/curroncol32070405
Abstract: Simple Summary Cholangiocarcinoma is a rare and aggressive cancer of the bile ducts. For some patients, this cancer is linked to a genetic change in the FGFR2 protein. In 2021, Health Canada approved pemigatinib as… read more here.
Keywords: patient support; pemigatinib; real world; cholangiocarcinoma ... See more keywords